The Russian Ministry of Health has granted a registration certificate to the Russian pharmaceutical company Promomed for the drug Tirzetta (tirzepatide), which is intended for weight loss and obesity treatment, including in patients with type 2 diabetes. Notably, the patent protection for tirzepatide, originally held by the American company Eli Lilly (manufacturer of the original drug Mounjaro), was terminated in Russia in November 2024 at the initiative of the patent holder itself, according to the Eurasian Patent Organization.
The registration certificate, now listed in the State Register of Medicinal Products, will remain valid until January 2030. Tirzetta will be available as a solution for subcutaneous injection in six different dosages (ranging from 2.5 mg to 15 mg). The drug will be produced in the form of prefilled injection pens, conventional syringes, and autoinjectors. Manufacturing and packaging will be handled by the pharmaceutical plants Biochemik and Medsintez.
“Tirzepatide represents a new class of incretin-based drugs that activate not one but two metabolism-regulating receptors—GLP-1 and GIP. Their combined action provides greater selectivity in regulating metabolism, insulin and blood glucose levels, and metabolic activity in specific tissues. As a result, weight loss primarily occurs due to enhanced fat metabolism,” Promomed states on its website.
